David McIntyre
Chief Financial Officer · Inhibikase Therapeutics, Inc.
Individual
- 2026
- Jan 7, 2026
- 1
Filings (90d)
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies David McIntyre files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Sands Capital Life Sciences Pulse Fund II, L.P. - $3.00M in IKT purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is David McIntyre?
David McIntyre is a corporate insider, tracked as Chief Financial Officer of Inhibikase Therapeutics, Inc. (IKT). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did David McIntyre last file a Form 4?
The only primary Form 4 on record is dated 7 January 2026.